Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Response Biomedical first-quarter total revenue down 43%

Response Biomedical first-quarter total revenue down 43%

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

NanoBio to develop intranasal vaccine for HBV

NanoBio to develop intranasal vaccine for HBV

Novartis withdraws EMA MAA for JOULFERON

Novartis withdraws EMA MAA for JOULFERON

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

sBioMed's anthrax killing sterilant receives EPA approval

sBioMed's anthrax killing sterilant receives EPA approval

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

AVANIR Pharmaceuticals presents Phase III trial data of Zenvia for PBA at AAN Annual Meeting

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Single vaccine for anthrax and plague: iBio confirms grant of rights

Single vaccine for anthrax and plague: iBio confirms grant of rights

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

Three scientific posters featuring Zenvia to be presented at AAN Annual Meeting

Cangene extends botulism antitoxin contract with BARDA

Cangene extends botulism antitoxin contract with BARDA

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

UNDT's 5-agent bioterrorism detection kits used by first responders

UNDT's 5-agent bioterrorism detection kits used by first responders

Aradigm reports net loss of $3.4M for fourth-quarter 2009

Aradigm reports net loss of $3.4M for fourth-quarter 2009

PharmAthene to provide update on contract modification suspension

PharmAthene to provide update on contract modification suspension

PharmAthene suspends work on SparVax research and development contract with BARDA

PharmAthene suspends work on SparVax research and development contract with BARDA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.